JAMA Neurology is a leading peer-reviewed journal published by the American Medical Association, focused on advancing the understanding and treatment of neurological disorders. With an impressive impact factor and ranked in the 99th percentile among clinical neurology journals, this publication is recognized as Q1 in its category for 2023, highlighting its significance in the field. Since its inception, the journal has provided a platform for high-quality research, clinical trials, and reviews that inform both clinicians and researchers. Operating from its headquarters in Chicago, Illinois, JAMA Neurology offers rich insights into the latest advancements in neurology, featuring articles that span a wide range of topics including neurodegenerative diseases, stroke, epilepsy, and neurocritical care. Researchers and professionals are encouraged to access the journal’s content freely, as it employs open access options to promote the dissemination of critical knowledge. As a critical resource in the field of neurology, JAMA Neurology is essential for anyone involved in this dynamic and rapidly evolving specialty.

Clinical and Experimental Medicine is a leading journal published by Springer-Verlag Italia SRL, dedicated to advancing the understanding of the intricate relationships between biomedical research and clinical applications. Since its inception in 2001, the journal has garnered an esteemed reputation, achieving Q1 quartile rankings in 2023 in both Biochemistry, Genetics and Molecular Biology (miscellaneous) and Medicine (miscellaneous), establishing itself as a key resource for researchers and practitioners alike. With an impactful contribution reflected in its Scopus rankings, particularly a #81/221 rank in the General Biochemistry, Genetics and Molecular Biology category, Clinical and Experimental Medicine serves as a rich platform for peer-reviewed articles that bridge theory and practice across diverse medical disciplines. The journal embraces Open Access options, broadening the accessibility of groundbreaking research to a global audience, thereby fostering collaboration and innovation. Located in Milan, Italy, it continually endeavors to enrich knowledge and share valuable insights essential for the advancement of health sciences.

NEUROLOGIC CLINICS, published by W B SAUNDERS CO-ELSEVIER INC, stands as a leading journal in the field of clinical neurology, boasting an impressive impact factor that reflects its significant contributions to neurological research and clinical practice. With an ISSN of 0733-8619 and E-ISSN of 1557-9875, this journal provides a critical platform for the dissemination of innovative research, case studies, and reviews focusing on various aspects of neurology, from diagnosis to treatment interventions. As part of its commitment to advancing the understanding of neurological disorders, NEUROLOGIC CLINICS is categorized in the Q2 quartile for Neurology (clinical) in 2023, indicating its robust standing within the academic community. It is recognized for its rigorous peer-review process and is indexed in Scopus, ranking #147 out of 400 in its field with a notable 63rd percentile. The journal, which dates back to 1983 and continues to publish vital findings up to 2024, is an invaluable resource for researchers, healthcare professionals, and students dedicated to enhancing their knowledge and clinical skills in neurology. Subscribe now to stay abreast of current advancements and expand your expertise in this dynamic field.

REVISTA DE NEUROLOGIA is a distinguished academic journal focusing on the broad fields of neurology and medicine, published in Spain since its inception in 1959. The journal plays a vital role in disseminating significant research findings, clinical studies, and advancements in neurological science, catering to an audience of researchers, clinicians, and students alike. With an ISSN of 0210-0010 and an E-ISSN of 1576-6578, this quarterly publication has maintained its commitment to enhancing the understanding of neurological disorders and therapies through rigorous peer-reviewed articles. While currently not classified as open access, it is indexed in Scopus, holding a rank of #253 out of 400 in the category of Medicine (Neurology), reflecting its relevance in the field with a 36th percentile. The journal is positioned within the Q3 quartile for both Medicine (miscellaneous) and Clinical Neurology categories as of 2023. Based in Barcelona, Spain, it is a vital resource for anyone devoted to the advancement of knowledge and practice in neurology.

Neurodegenerative Disease Management is a distinguished journal published by FUTURE MEDICINE LTD, focusing on the pivotal issues surrounding the management of neurodegenerative diseases. Since its inception in 2014, this journal has emerged as a significant resource within the fields of medicine and neurology, currently holding a respected position with a Q2 category ranking in Medicine (miscellaneous) and Q3 in Neurology (clinical) for 2023. With an ISSN of 1758-2024 and E-ISSN 1758-2032, the journal provides a platform for the dissemination of innovative research, clinical practices, and advancements in treatment strategies for conditions such as Alzheimer's, Parkinson's, and multiple sclerosis. The journal is particularly committed to enhancing knowledge sharing among researchers, health professionals, and students, contributing to the collective effort in combatting neurodegenerative diseases. Though not open access, its articles are meticulously curated to ensure high-quality, impactful contributions to the field, making it an essential reference for those engaged in neurology and related disciplines.

NEUROLOGIA, an esteemed journal published by ELSEVIER ESPANA SLU, stands at the forefront of the field of neurology, with a dedicated focus on innovative research and clinical practice since its inception in 1973. As an Open Access journal since 2017, it champions the dissemination of knowledge, allowing researchers, professionals, and students alike to access cutting-edge findings in neurology without barriers. With an impressive Scopus rank of #115 in the clinical neurology category, placing it in the 71st percentile, NEUROLOGIA is categorized as Q3 in both general medicine and clinical neurology, reflecting its impact and relevance in a rapidly evolving field. Based in Barcelona, Spain, the journal's commitment to advancing understanding of neurological conditions is underscored by its rigorous peer-review process and engagement with a global audience. As it continues to publish vital research that shapes clinical practices and informs policy, NEUROLOGIA remains an integral resource for those striving to improve outcomes in neurology.

Journal of Scleroderma and Related Disorders, published by SAGE Publications Ltd, stands as a key platform dedicated to advancing the understanding of scleroderma and related autoimmune disorders. With its ISSN of 2397-1983 and E-ISSN of 2397-1991, this esteemed journal has been contributing to the field since its inception in 2016 and continues to attract attention with its convergence period extending to 2024. The journal operates with an open access policy, thus enhancing the visibility and accessibility of research findings for healthcare professionals, researchers, and students worldwide. Recognized for its significant impact, it holds a Q3 quartile ranking in Immunology and Q2 rankings in Immunology and Allergy and Rheumatology in 2023, showcasing its relevance in these critical fields. Furthermore, the journal has achieved commendable Scopus rankings, positioning it firmly within the top echelons of its categories, particularly in Medicine - Rheumatology (#33/73, 55th percentile). With its comprehensive scope, the Journal of Scleroderma and Related Disorders plays a pivotal role in disseminating vital research that can influence treatment strategies and improve patient care for those suffering from scleroderma and its related conditions.

Welcome to the Journal of Central Nervous System Disease, a premier Open Access publication dedicated to advancing the understanding of neurological disorders and their underlying mechanisms. Published by SAGE Publications Ltd, this esteemed journal has been serving the scientific community since 2009 and is committed to disseminating high-quality research that spans from clinical neurology to cellular and molecular neuroscience. With an impressive impact factor, the journal ranks within the top quartiles—Q2 in both Neurology and Clinical Neurology, and Q3 in Cellular and Molecular Neuroscience as of 2023. The journal's indexing in Scopus reflects its significant contribution to the field, being ranked #83 out of 400 in clinical neurology and #38 out of 97 in cellular and molecular neuroscience. This essential resource, based in the United States, is crucial for researchers, clinicians, and students looking to stay at the forefront of neurological science. By providing Open Access options, we ensure that groundbreaking research is readily available to a global audience, fostering collaboration and innovation in the study of central nervous system diseases.

European Neurology, published by KARGER, is a distinguished journal in the field of neurology, catering to both clinical and neuroscience specialties. Since its inception in 1897 and continuing through 2024, the journal has been a vital platform for disseminating significant research findings and insights in neurology. With an ISSN of 0014-3022 and E-ISSN of 1421-9913, it ranks in the Q3 quartile in both clinical neurology and general neurology categories, reflecting its commitment to scholarly excellence while holding the 175th rank in clinical medicine and the 93rd in neuroscience, according to Scopus metrics. European Neurology facilitates a deeper understanding of neurological disorders and treatments, appealing to a diverse readership that includes researchers, clinicians, and students alike. Despite not currently offering open access, the journal’s rigorous peer-review process ensures that only high-quality research reaches its audience, making it an essential resource for those looking to stay informed in the rapidly evolving field of neurology.

Neurology and Therapy, published by SPRINGER LONDON LTD, stands as a pivotal platform for researchers and practitioners in the field of neurology and its therapeutic applications. This Open Access journal, active since 2012, facilitates the dissemination of innovative studies and cutting-edge findings aimed at improving neurological health. With an impressive ranking in the 2023 Scopus Rankings, where it holds a Q2 category in Neurology and a Q1 category in Clinical Neurology, it underscores its prominence in advancing neurological research. The journal's intriguing scope encompasses a wide-ranging exploration of neurological disorders, treatment methodologies, and healthcare strategies, making it a valuable resource for those vested in enhancing patient outcomes. With an appealing average impact factor, readers are encouraged to dive into the latest advancements and engage with the scholarly discussions that are shaping the future of neurology.